Harnessing the Power of Targeting c-Kit

Who We Are

Jasper is a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases.

Our mission is to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.

Learn More

Our Targeted Anti c-Kit Antibody

Briquilimab (formerly JSP191) is a targeted anti c-Kit monoclonal antibody designed to deplete mast cells and diseased stem cells as well as enable safer and more effective curative hematopoietic stem cell transplants and stem cell gene therapies.

Jasper is studying briquilimab across multiple diseases. Briquilimab is currently being studied as a therapeutic for chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID).

Learn More

Leadership Team

Jasper Therapeutics’ management team is composed of experienced biopharma industry veterans with extensive track records in drug development and commercialization.

With this leadership, we are well positioned to achieve our vision of developing new therapies to treat both chronic and life-threatening mast and stem cell diseases.

Learn More